BOTOX + Placebo for BOTOX
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Limb Essential Tremor (UL ET)
Conditions
Upper Limb Essential Tremor (UL ET)
Trial Timeline
Apr 12, 2022 → Feb 3, 2025
NCT ID
NCT05216250About BOTOX + Placebo for BOTOX
BOTOX + Placebo for BOTOX is a phase 2 stage product being developed by AbbVie for Upper Limb Essential Tremor (UL ET). The current trial status is completed. This product is registered under clinical trial identifier NCT05216250. Target conditions include Upper Limb Essential Tremor (UL ET).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06137287 | Phase 3 | Completed |
| NCT05216250 | Phase 2 | Completed |
| NCT05141006 | Phase 2 | Completed |
Competing Products
20 competing products in Upper Limb Essential Tremor (UL ET)